Tetra Tech's FY26 Backlog at $4.7B and 5% Q4 Revenue Growth Support Steady Recovery but Don't Alter WAIT Thesis

What happened

Tetra Tech ended fiscal 2026 with $4.7 billion in funded backlog and fourth quarter net revenue up 5% year over year to $1.15 billion. This print confirms the base-case trajectory after the USAID shock, as the company pivots to defense, water, and international work. The backlog figure is well above the $3.92 billion RUPO reported earlier in the year, indicating solid order conversion and a stronger forward revenue base. However, the $115 million Hunters Point legal contingency and potential EPA/SRF funding cuts remain unresolved risks that could pressure earnings. At around $39, the stock still trades at 21–22x forward EPS, offering limited margin of safety, so the WAIT rating stands.

Implication

Investors should view the FY26 results as steady progress rather than a catalyst to chase the stock. The 5% net revenue growth in Q4 indicates that ex-USAID revenue is stabilizing, and the $4.7B funded backlog provides visibility into FY27. However, the legal overhang from Hunters Point has not been fully resolved, and appropriations for EPA/SRF programs could still tighten. The stock's ~21–22x forward EPS multiple prices in mid-single-digit growth with modest margin expansion, leaving little room for error. A more attractive entry would be near $34, or after two consecutive quarters of ≥6% ex-USAID growth with margin expansion, before upgrading from WAIT.

Thesis delta

The FY26 funded backlog of $4.7B and Q4 net revenue growth of 5% provide incremental evidence that Tetra Tech is offsetting USAID losses with defense and water work, but one quarter does not eliminate the legal tail risk or funding uncertainty. The WAIT thesis remains intact: investors should still prefer a pullback toward $34 or two more quarters of ≥6% ex-USAID growth before upgrading.